Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy

Cardiovascular Ultrasound

Volumn 7, Issue 1, 2009, Pages

  Magne, Julien ^a   Dubois, Michelle ^a   Champagne, Jean ^a   Dumesnil, Jean G ^a   Pibarot, Philippe ^a   Philippon, François ^a   Ohara, Gilles ^a   Sénéchal, Mario ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; DIAGNOSTIC ACCURACY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HUMAN; MALE; MITRAL VALVE REGURGITATION; PATIENT MONITORING; SENSITIVITY AND SPECIFICITY; STRESS ECHOCARDIOGRAPHY; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART PACING; METHODOLOGY; PROGNOSIS; REPRODUCIBILITY;

AGED; BIOLOGICAL MARKERS; CARDIAC PACING, ARTIFICIAL; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 70349243226     PISSN: None     EISSN: 14767120     Source Type: Journal    
DOI: 10.1186/1476-7120-7-39     Document Type: Article

References (35)

1. The effect of cardiac resynchronization on morbidity and mortality in heart failure. JG Cleland JC Daubert E Erdmann N Freemantle D Gras L Kappenberger, et al. N Engl J Med 2005 352 1539 1549 10.1056/NEJMoa050496 15753115 (Pubitemid 40517094)
2. Cardiac resynchronization in chronic heart failure. WT Abraham WG Fisher AL Smith DB Delurgio AR Leon E Loh, et al. N Engl J Med 2002 346 1845 1853 10.1056/NEJMoa013168 12063368
3. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. C Linde C Leclercq S Rex S Garrigue T Lavergne S Cazeau, et al. J Am Coll Cardiol 2002 40 111 118 10.1016/S0735-1097(02)01932-0 12103264
4. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. MR Bristow LA Saxon J Boehmer S Krueger DA Kass T De Marco, et al. N Engl J Med 2004 350 2140 2150 10.1056/NEJMoa032423 15152059
5. Effect of cardiac resynchronization therapy on functional mitral regurgitation in heart failure. P Lancellotti P Melon N Sakalihasan A Waleffe C Dubois M Bertholet, et al. Am J Cardiol 2004 94 1462 1465 10.1016/j.amjcard. 2004.07.154 15566929
6. Early and late effects of cardiac resynchronization therapy on exercise-induced mitral regurgitation: relationship with left ventricular dyssynchrony, remodelling and cardiopulmonary performance. J Madaric M Vanderheyden C Van Laethem K Verhamme A Feys M Goethals, et al. Eur Heart J 2007
7. A mechanism for immediate reduction in mitral regurgitation after cardiac resynchronization therapy: insights from mechanical activation strain mapping. H Kanzaki R Bazaz D Schwartzman K Dohi LE Sade J Gorcsan III, J Am Coll Cardiol 2004 44 1619 1625 10.1016/j.jacc.2004.07.036 15489094
8. Time course of effects of cardiac resynchronization therapy in chronic heart failure: benefits in patients with preserved exercise capacity. MF Piepoli GQ Villani U Corra D Aschieri G Rusticali, Pacing Clin Electrophysiol 2008 31 701 708 10.1111/j.1540-8159.2008.01073.x 18507542
9. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. RW Troughton CM Frampton TG Yandle EA Espiner MG Nicholls AM Richards, Lancet 2000 355 1126 1130 10.1016/S0140-6736(00)02060-2 10791374
10. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. DR Murdoch TA McDonagh J Byrne L Blue R Farmer JJ Morton, et al. Am Heart J 1999 138 1126 1132 10.1016/S0002-8703(99)70079-7 10577444
11. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. FM Fruhwald A Fahrleitner-Pammer R Berger F Leyva N Freemantle E Erdmann, et al. Eur Heart J 2007 28 1592 1597 10.1093/eurheartj/ehl505 17298973
12. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. P de Groote J Dagorn B Soudan N Lamblin E McFadden C Bauters, J Am Coll Cardiol 2004 43 1584 1589 10.1016/j.jacc.2003.11.059 15120815
13. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. WA Zoghbi M Enriquez-Sarano E Foster PA Grayburn CD Kraft RA Levine, et al. J Am Soc Echocardiogr 2003 16 777 802 10.1016/S0894-7317(03)00335-3 12835667
14. Intra-left ventricular electromechanical asynchrony. A new independent predictor of severe cardiac events in heart failure patients. H Bader S Garrigue S Lafitte S Reuter P Jais M Haissaguerre, et al. J Am Coll Cardiol 2004 43 248 256 10.1016/j.jacc.2003.08.038 14736445
15. Impact of contractile reserve on acute response to cardiac resynchronization therapy. M Moonen M Senechal B Cosyns P Melon E Nellessen L Pierard, et al. Cardiovasc Ultrasound 2008 6 65 19117517
16. Myocardial contractile reserve during exercise predicts left ventricular reverse remodelling after cardiac resynchronization therapy. P Lancellotti M Senechal M Moonen E Donal J Magne E Nellessen, et al. Eur J Echocardiogr 2009 10 663 8 10.1093/ejechocard/jep033 19351652
17. Identification of responders to cardiac resynchronization therapy by contractile reserve during stress echocardiography. Q Ciampi L Pratali R Citro M Piacenti B Villari E Picano, Eur J Heart Fail 2009 11 489 496 10.1093/eurjhf/hfp039 19324921
18. Decrease in plasma B-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months. M Kubanek I Malek J Bytesnik P Fridl L Riedlbauchova L Karasova, et al. Eur J Heart Fail 2006 8 832 840 10.1016/j.ejheart.2006.02.006 16546444
19. Predictors of remodeling in the CRT era: influence of mitral regurgitation, BNP, and gender. TP Cappola MR Harsch M Jessup WT Abraham JB Young S Petersen-Stejskal, et al. J Card Fail 2006 12 182 188 10.1016/j.cardfail.2005.11.003 16624682
20. Suboptimal medical therapy in patients with systolic heart failure is associated with less improvement by cardiac resynchronization therapy. JW Fung JY Chan LC Kum HC Chan GW Yip Q Zhang, et al. Int J Cardiol 2007 115 214 219 10.1016/j.ijcard.2006.04.034 16797091
21. Prognostic value of brain natriuretic peptide in the management of patients receiving cardiac resynchronization therapy. MV Pitzalis M Iacoviello F Di Serio R Romito P Guida E De Tommasi, et al. Eur J Heart Fail 2006 8 509 514 10.1016/j.ejheart.2005.10.013 16503416
22. Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy. N Lellouche C De Diego DA Cesario M Vaseghi BN Horowitz A Mahajan, et al. Am J Cardiol 2007 99 242 246 10.1016/j.amjcard.2006.08.018 17223426
23. Electromechanical effects of cardiac resynchronization therapy during rest and stress in patients with heart failure. C Valzania F Gadler MJ Eriksson A Olsson G Boriani F Braunschweig, Eur J Heart Fail 2007 9 644 650 10.1016/j.ejheart.2007.01.009 17347041
24. Coronary and peripheral blood flow changes following biventricular pacing and their relation to heart failure improvement. P Flevari G Theodorakis I Paraskevaidis F Kolokathis A Kostopoulou D Leftheriotis, et al. Europace 2006 8 44 50 10.1093/europace/euj015 16627408
25. Tissue Doppler imaging predicts improved systolic performance and reversed left ventricular remodeling during long-term cardiac resynchronization therapy. P Sogaard H Egeblad WY Kim HK Jensen AK Pedersen BO Kristensen, et al. J Am Coll Cardiol 2002 40 723 730 10.1016/S0735-1097(02)02010-7 12204503
26. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. JA White R Yee X Yuan A Krahn A Skanes M Parker, et al. J Am Coll Cardiol 2006 48 1953 1960 10.1016/j.jacc.2006.07.046 17112984
27. Nuclear imaging in cardiac resynchronization therapy. MM Henneman EE van der Wall C Ypenburg GB Bleeker NR Van de Veire NA Marsan, et al. J Nucl Med 2007 48 2001 2010 10.2967/jnumed.107.040360 18056333
28. Late gadolinium enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. S Chalil PW Foley SA Muyhaldeen KC Patel ZR Yousef RE Smith, et al. Europace 2007 9 1031 1037 10.1093/europace/eum133 17933857
29. Myocardial contractile reserve predicts improvement in left ventricular function after cardiac resynchronization therapy. C Ypenburg A Sieders GB Bleeker ER Holman EE van der Wall MJ Schalij, et al. Am Heart J 2007 154 1160 1165 10.1016/j.ahj.2007.07.035 18035090
30. Importance of contractile reserve for CRT. P Lim C Bars L Mitchell-Heggs C Roiron N Elbaz B Hamdaoui, et al. Europace 2007 9 739 743 10.1093/europace/ eum117 17573360
31. Prospective validation of stress echocardiography as an identifier of cardiac resynchronization therapy responders. A Da Costa J Thevenin F Roche E Faure C Romeyer-Bouchard M Messier, et al. Heart Rhythm 2006 3 406 413 10.1016/j.hrthm.2005.12.017 16567286
32. Extent of viability to predict response to cardiac resynchronization therapy in ischemic heart failure patients. C Ypenburg MJ Schalij GB Bleeker P Steendijk E Boersma P Dibbets-Schneider, et al. J Nucl Med 2006 47 1565 1570 17015888
33. Presence of left ventricular contractile reserve, evaluated by means of dobutamine stress-echo test, is able to predict response to cardiac resynchronization therapy. B Tuccillo C Muto R Iengo M Accadia S Rumolo M Canciello, et al. J Interv Card Electrophysiol 2008 23 121 126 10.1007/s10840-008-9255-9 18587637
34. Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. WL Miller KA Hartman DE Grill JC Burnett Jr AS Jaffe, Clin Chem 2009 55 78 84 10.1373/clinchem.2008.108928 19028821
35. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. CM Yu GB Bleeker JW Fung MJ Schalij Q Zhang EE van der Wall, et al. Circulation 2005 112 1580 1586 10.1161/CIRCULATIONAHA.105.538272 16144994